The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy
Authors
Keywords
PD-1/PD-L1, Breast cancer, Immunotherapy, Monotherapy, Combination therapies
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 895, Issue -, Pages 173867
Publisher
Elsevier BV
Online
2021-01-15
DOI
10.1016/j.ejphar.2021.173867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of brain metastases in breast cancer: a review of current practices and emerging treatments
- (2020) Matthew N. Mills et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunotherapies for pediatric cancer: current landscape and future perspectives
- (2020) Brian Hutzen et al. CANCER AND METASTASIS REVIEWS
- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer
- (2020) Romualdo Barroso-Sousa et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
- (2020) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
- (2020) Leitao Sun et al. Scientific Reports
- A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.
- (2020) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer
- (2020) Zhi Bing Liu et al. OncoTargets and Therapy
- The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
- (2020) Run-Cong Nie et al. Biomed Research International
- Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
- (2020) Regina Padmanabhan et al. Cancers
- Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer
- (2020) Zhuzhu Wu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
- (2019) Iosune Baraibar et al. DRUG SAFETY
- PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
- (2019) Yongshuai Jiang et al. Human Vaccines & Immunotherapeutics
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
- (2019) Jeremy Force et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.
- (2019) Jin Sun Lee-Bitar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
- (2019) David B. Page et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
- (2019) Adam Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Consideration of breast cancer subtype in targeting the androgen receptor
- (2019) Clasina M. Venema et al. PHARMACOLOGY & THERAPEUTICS
- Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
- (2019) Wei Xiong Wen et al. PLoS One
- Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
- (2019) Aradhana Rani et al. Frontiers in Endocrinology
- Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
- (2019) Chrétien et al. Cancers
- Durvalumab in cancer medicine: a comprehensive review
- (2019) Juliana Alvarez-Argote et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents
- (2019) Samuel Ofori et al. ACS Omega
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
- (2019) Sanjeevani Arora et al. ADVANCES IN THERAPY
- Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
- (2019) Lorena Incorvaia et al. ADVANCES IN THERAPY
- Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
- (2019) Suliman Almahmoud et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
- (2019) Chenxi Yuan et al. Scientific Reports
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
- (2019) Luciana Molinero et al. Journal for ImmunoTherapy of Cancer
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of immune evasion in breast cancer
- (2018) Joshua P. Bates et al. BMC CANCER
- Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
- (2018) Ming Li et al. BMC CANCER
- Immunotherapy in breast cancer: An introduction
- (2018) Mary L. Disis et al. BREAST
- Checkpoint blockade in the treatment of breast cancer: current status and future directions
- (2018) Lironne Wein et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
- (2018) Tao Shi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapeutic interventions of Triple Negative Breast Cancer
- (2018) Zehuan Li et al. Journal of Translational Medicine
- Development of selective androgen receptor modulators (SARMs)
- (2018) Ramesh Narayanan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Luminal A Breast Cancer and Molecular Assays: A Review
- (2018) Jennifer J. Gao et al. ONCOLOGIST
- Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
- (2018) Hannah A. Blair Targeted Oncology
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
- (2018) Cesar August Santa-Maria et al. Oncotarget
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer
- (2018) Yanjun Hou et al. Breast Journal
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
- (2018) Yang Liu et al. Journal of Hematology & Oncology
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- 1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
- (2018) K P Papadopoulos et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
- (2018) Quirine F. Manson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Emerging therapies for breast cancer
- (2017) Xichun Hu et al. Journal of Hematology & Oncology
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation
- (2017) Ying Zhao et al. ONCOLOGY REPORTS
- Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
- (2017) François Bertucci et al. Current Oncology Reports
- Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
- (2017) Dorothea Sonja Schott et al. Oncotarget
- New Immunotherapy Strategies in Breast Cancer
- (2017) Lin-Yu Yu et al. International Journal of Environmental Research and Public Health
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- PD-1/PD-L1 Pathway in Breast Cancer
- (2017) Florian Schütz et al. Oncology Research and Treatment
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
- (2017) Karim Rihawi et al. Therapeutic Advances in Respiratory Disease
- Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
- (2017) Fei Zhang et al. Cell Discovery
- Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
- (2016) Ashish Kulkarni et al. ACS Nano
- Checkpoint Inhibitors and Their Application in Breast Cancer
- (2016) Davide Bedognetti et al. Breast Care
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
- (2016) Wei Xue et al. Oncotarget
- Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
- (2016) Ramesh Narayanan et al. Cancers
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Critical role of CDK11p58 in human breast cancer growth and angiogenesis
- (2015) Yayun Chi et al. BMC CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
- (2015) Elizabeth Buchbinder et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- New immunotherapies targeting the PD-1 pathway
- (2015) Jordan M. Chinai et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands
- (2014) Pinar Karasar et al. BREAST CANCER RESEARCH AND TREATMENT
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
- (2014) Kim A Reiss et al. Immunotherapy
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- The treatment and survival of patients with triple negative breast cancer in a London population
- (2014) Shrestha Pal et al. SpringerPlus
- Androgen Receptor (AR) Physiological Roles in Male and Female Reproductive Systems: Lessons Learned from AR-Knockout Mice Lacking AR in Selective Cells1
- (2013) Chawnshang Chang et al. BIOLOGY OF REPRODUCTION
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Cancer and Radiation Therapy: Current Advances and Future Directions
- (2012) Rajamanickam Baskar et al. International Journal of Medical Sciences
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- (2011) James T. Dalton et al. Journal of Cachexia Sarcopenia and Muscle
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
- (2009) Ashok Agarwal et al. Reproductive Biology and Endocrinology
- The Role of Androgens in Normal and Malignant Breast Tissue
- (2008) Katharina Tiefenbacher et al. Breast Care
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More